Delandistrogene moxeparvovec showed potential in slowing Duchenne muscular dystrophy progression compared with placebo, based on muscle QMR measures. The phase 3 EMBARK clinical trial provided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results